 |
市場調查報告書
商品編碼
1122402
骨髓增生異常綜合徵治療市場：按代理、管理途徑、分銷渠道、地區 - 規模、份額、前景和機會分析，2022-2030Myelodysplastic Syndrome Treatment Market, by Drug, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
價格
簡介目錄
骨髓增生異常綜合徵是一組癌症，其中骨髓中的未成熟血細胞未成熟並成為健康血細胞。根據血細胞和骨髓的某些變化來診斷骨髓增生異常綜合徵的類型。骨髓增生異常綜合徵 (MDS) 是一種罕見的血癌，其中沒有足夠的健康血細胞。也稱為骨髓增生異常綜合徵。 MDS 有多種類型。在 MDS 中，骨髓中的一些細胞異常（發育異常）並且難以製造新的血細胞。這些骨髓細胞形成的一些血細胞是有缺陷的。有缺陷的細胞通常比正常細胞死亡得更快，身體會破壞異常血細胞，導致正常血細胞短缺。骨髓增生異常綜合徵最常見的發現是缺乏紅細胞（貧血），但許多不同的細胞類型都會受到影響。治療相關的 MDS 是骨髓增生異常綜合徵的一種亞型。它是由先前癌症的化學療法或放射療法引起的。在美國，骨髓增生異常綜合徵和與治療相關的骨髓增生異常綜合徵的新診斷正在增加。這是因為老年人口正在增加，癌症治療後人們的壽命更長。
市場動態
阿扎胞甘在北美、拉丁美洲、歐洲、亞太地區、非洲等關鍵地區的上市和批准數量不斷增加，預計將在預測期內推動骨髓增生異常綜合徵治療市場阿扎胞甘部分的增長。例如，2018年2月，百濟神州生物技術公司宣布VIDAZ（注射用阿扎胞甘）在中國上市。 VIDAZA 在中國已獲批用於中/高危骨髓增生異常綜合徵（MDS）、20-30% 成髓細胞的急性髓細胞白血病（AML）和慢性粒單核細胞白血病（CMML）患者。在中國，它由百濟神州根據新基公司（製藥公司）的獨家許可進行銷售。
本研究的主要特點
- 本報告對全球骨髓增生異常綜合徵 (MDS) 治療市場進行了深入分析，揭示了以 2021 年為基準年的預測期內（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。 ) 提供。
- 它揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資建議矩陣。
- 它還提供關鍵見解，例如市場驅動因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略。
- 根據公司亮點、產品組合、關鍵亮點、業績和戰略等參數，介紹了全球骨髓增生異常綜合徵 (MDS) 治療市場中的主要參與者的概況。
- 本研究涉及的主要公司包括 Celgene Corporation、Otsuka Pharmaceutical Co., Ltd.、Teva Pharmaceutical Industries Ltd.、Sun Pharmaceutical Industries Limited、Dr. Reddy's Laboratories Ltd.、Mylan NV、Cipla Limited、Acceleron Pharma, Inc .、Area Therapeutics、FibroGen Inc.、Onconova Therapeutics Inc. 和 Geron。
- 本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
- 全球骨髓增生異常綜合徵 (MDS) 治療市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。1.
- 利益相關者可以通過用於分析全球骨髓增生異常綜合徵 (MDS) 治療市場的各種戰略矩陣來促進他們的決策。
內容
第 1 章目的和先決條件
- 調查目的
- 先決條件
- 縮寫說明
第二章市場展望
- 舉報內容
- 市場定義和範圍
- 執行摘要
- 市場快照：按藥物分類
- 按管理途徑劃分的市場概況
- 市場快照：按分銷渠道
- 市場概況：按地區劃分
- 連貫的機會圖 (COM)
第 3 章市場動態、法規和趨勢分析
- 市場動態
- 驅動程序
- 約束因素
- 市場機會
- 影響分析
- 市場趨勢
- 近期趨勢
- 收購和合作方案
- 技術概述
- 監管場景
- 價格分析
- PEST 分析
第 4 章全球骨髓增生異常綜合徵 (MDS) 治療市場 - 冠狀病毒 (COVID-19) 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第 5 章。2017-2030 年按代理分列的全球骨髓增生異常綜合徵 (MDS) 治療市場
- 來那度胺
- 地西他濱
- 阿扎胞甘
- 第 3 階段藥物
第 6 章。按給藥途徑分列的骨髓增生異常綜合徵 (MDS) 治療的全球市場：2017-2030 年
- 注入
- 口語
第 7 章。全球骨髓增生異常綜合徵 (MDS) 治療市場：按分銷渠道，2017-2030 年
- 醫院藥房
- 零售藥房
- 在線藥店
第 8 章。2017-2030 年按地區分列的全球骨髓增生異常綜合徵 (MDS) 治療市場
- 北美
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲地區
- 歐洲
- 英國
- 德國
- 意大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 東盟
- 澳大利亞
- 韓國
- 其他亞太地區
- 中東
- 海合會
- 以色列
- 其他中東
- 非洲
- 北非
- 中非
- 南非
第 9 章競爭格局
- 熱圖分析
- 公司簡介
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Dr. Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
第 10 章
- 參考資料
- 調查方法介紹
- 關於出版商
簡介目錄
Product Code: CMI775
Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The different types of myelodysplastic syndromes are diagnosed based on certain changes in the blood cells and bone marrow. Myelodysplastic syndromes (MDS) are a type of rare blood cancers where don't have enough healthy blood cells. It is also known as myelodysplasia. There are several different types of MDS. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Several of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in Myelodysplastic syndromes is a shortage of red blood cells (anemia). Therapy-related MDS is a subtype of Myelodysplastic syndromes. It is caused by treatment with chemotherapy or radiation therapy for a previous cancer. In the U.S., the number of new diagnoses of Myelodysplastic syndromes and therapy-related Myelodysplastic syndromes are both rising. This is because older people make up a growing segment of the population and people now live longer after treatment for cancer.
Market Dynamics
Increasing launch and approval of Azacitidine in key regions namely North America, Latin America, Europe, Asia Pacific, and Africa etc. is expected to drive growth of Azacitidine segment of the myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. Biotechnology Company announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation (Pharmaceutical Company).
Key features of the study:
- This report provides an in-depth analysis of the global myelodysplastic syndrome (MDS) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myelodysplastic syndrome (MDS) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myelodysplastic syndrome (MDS) treatment market
Detailed Segmentation:
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug :
- Lenalidomide
- Decitabine
- Azacitidine
- Phase 3 Drugs
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration:
- Injection
- Oral
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Celgene Corporation
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
- Celgene Corporation
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Myelodysplastic Syndrome (MDS) Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Lenalidomide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Decitabine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Azacitidine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Phase 3 Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
6. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Injection
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
8. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Region, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sun Pharmaceutical Industries Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mylan NV
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cipla Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Acceleron Pharma, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Aprea Therapeutics
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- FibroGen Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Onconova Therapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Geron
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
